Resolution of Menetrier's disease after Helicobacter pylori eradication therapy.
Hamlin
M
M
Sir Charles Gairdner Hospital, Perth, Western Australia.
Shepherd
K
K
Kennedy
M
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004044:Dietary Proteins / Q000008:administration & dosage; D005758:Gastritis, Hypertrophic / Q000188:drug therapy* / Q000382:microbiology* / Q000503:physiopathology; D005773:Gastroscopy; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D013454:Sulfoxides / Q000627:therapeutic use*; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D004044:Dietary Proteins; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole